SCHEMBL1338829

SCHEMBL1338829

Cn1c(=O)c(-c2ccc(F)cc2)cc2c3cc(-c4csc(N)n4)ccc3n(C)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ ALOX5 P09917 1/20 0.47
▸ MAPT P10636 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ GABRA1 P14867 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ MPL P40238 2/20 0.38
▸ AR P10275 4/20 0.37
▸ NFKB1 P19838 1/20 0.36
▸ GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1340004 0.90 LTA4H (0.43) ALDH1A1RAB9AMAPTMEN1KMT2A
SCHEMBL1339145 0.87 HPGD (0.39) ALDH1A1RAB9ASMN1; SMN2NPC1GAA
SCHEMBL1339370 0.83 L3MBTL1 (0.40) ALDH1A1RAB9AMAPTKDM4ESMN1; SMN2
SCHEMBL1336944 0.82 MAPK14 (0.36) RAB9AKDM4EGABRA1GABRG2GABRB3
SCHEMBL1339432 0.82 CNR1 (0.40) ALDH1A1RAB9AALOX5KDM4ESMN1; SMN2
SCHEMBL1338126 0.80 L3MBTL1 (0.61) ALDH1A1RAB9AMAPTMEN1KMT2A
SCHEMBL1339356 0.79 LMNA (0.43) ALDH1A1SMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL1336985 0.79 MAPK14 (0.37) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL1338328 0.78 LMNA (0.39) ALDH1A1RAB9AMAPTMEN1KMT2A
SCHEMBL1339304 0.77 PTGS2 (0.39) ALDH1A1RAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ALDH1A1 283/4885RAB9A 2067/4885ALOX5 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback